| Influence of cell proportions and proliferation rates on FDG uptake in squamous-cell esophageal carcinoma: a PET study. | |
| | |
MedLine Citation:
|
PMID: 18454686 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: We investigated the influence of cell proportions and proliferation activities on tumor maximum standard uptake value (SUV(max)) in patients with squamous-cell esophageal cancer (SCEC). METHODS: Sixteen (16) patients with untreated SCEC were examined with (18)F-flourodeoxyglucose positron emission tomography (FDG-PET). The tumor SUV(max) were calculated. Tumors were resected by transthoracic esophagectomy. Tissues were stained with hematoxylin and eosin for the measurement of cell proportions and MIB-1 for measurement of proliferation indices (PIs). Tumor SUV and histologic data were related by using multiple linear regression analysis. RESULTS: The mean proportion of tumor cells in the tumor site was 58.1% (+/-12.1%); the proportion of inflammatory cells was 34.2% (+/-14.2%); the PI of tumor cells was 70.5% (+/-11.8%); and the PI of inflammatory cells was 22.2% (+/-7.6%). The tumor PI was the only variable that was significantly associated with the FDG uptake in the tumor site (p = 0.04). The correlation was low (Pearson-coefficient Gamma = 0.51). The Pearson-correlation-coefficient between tumor SUV and the fraction of inflammatory cells was Gamma = 0.37 and between tumor SUV and PI of inflammatory cells Gamma = 0.13. CONCLUSIONS: In untreated SCEC-patients, the tumor maximum FDG uptake is weakly associated with the proliferation rate of tumor cells. In contrast, neither the proportion nor the PI of inflammatory cells in the tumor site significantly correlates with the maximum SUV and should not profoundly affect PET interpretations. |
| | |
Authors:
|
Inga Buchmann; Uwe Haberkorn; Irene Schmidtmann; Christoph Brochhausen; Hans-Georg Buchholz; Peter Bartenstein; Torsten Hansen |
Related Documents
:
|
3251896 - Systemic perfusion: a method of enhancing relative tumor uptake of radiolabeled monoclo... 18804696 - Exploitation of the folate receptor in the management of cancer and inflammatory disease. 8046606 - Pharmacokinetics of an antibody-ricin conjugate administered intraperitoneally to mice. 2297726 - Preclinical evaluation of an "instant" 99mtc-labeling kit for antibody imaging. 6581366 - Lack of correlation of growth attenuation of murine lymphoma caused by in vitro passage... 2666906 - Oncogenes conferring metastatic potential induce increased branching of asn-linked olig... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Cancer biotherapy & radiopharmaceuticals Volume: 23 ISSN: 1557-8852 ISO Abbreviation: Cancer Biother. Radiopharm. Publication Date: 2008 Apr |
Date Detail:
|
Created Date: 2008-05-05 Completed Date: 2008-08-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9605408 Medline TA: Cancer Biother Radiopharm Country: United States |
Other Details:
|
Languages: eng Pagination: 172-80 Citation Subset: IM |
Affiliation:
|
Klinik und Poliklinik für Nuklearmedizin, Universitätskliniken Mainz, Mainz, Germany. inga.buchmann@med.uni-heidelberg.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Carcinoma, Squamous Cell / metabolism, pathology*, radionuclide imaging* Cell Proliferation Cell Size Esophageal Neoplasms / metabolism, pathology*, radionuclide imaging* Female Fluorodeoxyglucose F18 / diagnostic use*, metabolism* Humans Immunohistochemistry Male Middle Aged Positron-Emission Tomography |
| Chemical | |
Reg. No./Substance:
|
63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agen...
Next Document: Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-la...